Projects per year
Personal profile
Biography
OCRF L’Oreal Paris Research Fellow
Ovarian Cancer Biomarkers/Steroid Receptor Biology
Hudson Institute for Medical Research
Dr. Simon Chu completed his PhD at Prince Henry’s Institute (PHI) in 2005. His studies focused on the roles of the estrogen receptor in the pathogenesis of a subset of ovarian tumours, and in particular, the impact that molecular signalling pathways of the cell have on this receptor. After gaining his PhD, Dr. Chu continued his work at PHI, examining the consequences of blocking this mechanism using new therapeutic compounds to explore whether this might lead to a new chemotherapeutic approach to treating this disease.
In 2007, Dr Chu left PHI to take up a postdoctoral position at the Pasteur Institute located in Cambodia, where he helped develop a new molecular technique to investigate the incidence of exposure to avian influenza in the human population in that country.
On his return to Australia in April 2009, Dr Chu joined PHI as the OCRF L’Oreal Paris Australia Research Fellow. His work focuses on the underlying causes of the more common type of ovarian cancer, as well as the less common granulosa cell tumour of the ovary. He is currently investigating an exciting potential therapeutic option for treating these cancers, using a combination treatment that targets two important biological pathways in the cancer cells. This presents a new chemotherapeutic approach for the treatment of ovarian cancer.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Collaborations and top research areas from the last five years
-
Advancing Ovarian Granulosa Cell Tumor Treatment: Structural Insights and Drug Discovery for the FOXL2C134W Mutation
Chu, S. (Primary Chief Investigator (PCI)), Wong, W. (Chief Investigator (CI)), Fuller, P. (Chief Investigator (CI)), Jobling, T. (Associate Investigator (AI)), Rosenbluh, S. (Associate Investigator (AI)) & Silke, J. (Associate Investigator (AI))
1/07/25 → 30/06/28
Project: Research
-
NHMRC Equipment Grant - Acid-Resistant CentriVap Centrifugal Vacuum Concen
Faridi, P. (Primary Chief Investigator (PCI)), Firestein, R. (Chief Investigator (CI)), Chu, S. (Chief Investigator (CI)), Schittenhelm, R. (Chief Investigator (CI)) & Lim, T. (Chief Investigator (CI))
1/11/23 → 31/12/23
Project: Research
-
The MPCCC Precision Medicine Scholarship
Chu, S. (Primary Chief Investigator (PCI)) & Fuller, P. (Chief Investigator (CI))
6/12/21 → 16/12/24
Project: Research
-
Precision Oncology: Directing New Therapeutic Interventions for Ovarian Cancer Patients
Stephens, A. (Primary Chief Investigator (PCI)), Bilandzic, M. (Chief Investigator (CI)), Firestein, R. (Chief Investigator (CI)), Hertzog, P. (Chief Investigator (CI)), Chu, S. (Chief Investigator (CI)), DeFazio, A. (Chief Investigator (CI)), Bowtell, D. D. L. (Chief Investigator (CI)), Jobling, T. (Associate Investigator (AI)), Goss, G. (Associate Investigator (AI)) & Kryzs, N. (Associate Investigator (AI))
1/01/20 → 31/12/20
Project: Research
-
Bazedoxifene – A New Selective Estrogen Receptor Modulator Treatment for People with Schizophrenia
Kulkarni, J. (Primary Chief Investigator (PCI)), Gurvich, C. (Chief Investigator (CI)), Thomas, N. (Chief Investigator (CI)), Sundram, S. (Chief Investigator (CI)), Hill, R. (Chief Investigator (CI)) & Chu, S. (Chief Investigator (CI))
1/06/19 → 31/05/22
Project: Research
-
Patient-Derived Xenograft Models for Ovarian Cancer
Tran, T. M., Ho, G. Y. & Chu, S., 2024, Methods in Molecular Biology. Saad, M. I. (ed.). New York NY USA: Humana Press, p. 187-196 10 p. (Methods in Molecular Biology; vol. 2806).Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review
1 Citation (Scopus) -
How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor (GCT) Survivor Sisters Facebook group member survey
White, V. M., Alexiadis, M., Eroh, K. D., Ackermann, M. K., Rodgers, S., Langdale, L. M., Armour, N. E., Jobling, T. W., Fuller, P. J. & Chu, S., 15 Jul 2023, In: Cancer. 129, 14, p. 2224–2234 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
FOXL2C134W: much ado about something!†
Fuller, P. J., Nguyen, T., Alexiadis, M. & Chu, S., Jan 2022, In: Journal of Pathology. 256, 1, p. 1-3 3 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access3 Citations (Scopus) -
Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Leung, D. T. H., Nguyen, T., Oliver, E. M., Matti, J., Alexiadis, M., Silke, J., Jobling, T. W., Fuller, P. J. & Chu, S., 1 Feb 2019, In: Molecular Cancer Therapeutics. 18, 2, p. 364-375 12 p.Research output: Contribution to journal › Article › Research › peer-review
17 Citations (Scopus) -
Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing
Alexiadis, M., Rowley, S. M., Chu, S., Leung, D. T. H., Stewart, C. J. R., Amarasinghe, K. C., Campbell, I. G. & Fuller, P. J., 1 Jan 2019, In: Molecular Cancer Research. 17, 1, p. 177-185 9 p.Research output: Contribution to journal › Article › Research › peer-review
47 Citations (Scopus)